Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Conclusions:Previously, there were limited data on the relationship between LCT status and clinical outcome or CD30 expression in MF pts treated with brentuximab vedotin. Our analyses demonstrated that pts with MF benefitted from brentuximab vedotin regardless of LCT status. A wide range of CD30 expression levels was observed in pts with MF and LCT. In these pts, high baseline CD30 expression levels were generally predictive of a good response to treatment with brentuximab vedotin although meaningful responses were observed in those with lower CD30 levels.DisclosuresKim: Merck: Research Funding; Eisai: Membership on an entity's Board of Directors or advisory committees, Research Funding; Tetralogic: Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees; Innate Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; miRagen: Research Funding; Medivir: Membership on an entity's Board of Directors or advisory committees; Kyowa-Kirin-Pharma: Membership on an entity's Board of Directors or advisory committees, Research Funding; Horizon Pharma: Consultancy, Research Funding; Portola: Research Funding; Soligenix: Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Galderma: Research Funding; Forty Seven Inc: Research Funding; Neumedicine: Consultancy, Research Funding. Prince: Celgene: Honoraria, Membership on an entity's ...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Poster I Source Type: research